Ischemic Stroke Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight's, "Ischemic Stroke Pipeline Insight, 2026" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Ischemic Stroke pipeline landscape. It covers the Ischemic Stroke pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Ischemic Stroke pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Ischemic Stroke Pipeline @ https://www.delveinsight.com/sample-request/ischemic-stroke-pipeline-insight [https://www.delveinsight.com/sample-request/ischemic-stroke-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Ischemic Stroke Pipeline Report

* On July 06, 2026- Janssen Research & Development LLC initiated a phase 3 study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.
* On June 29, 2026- Fujian Shengdi Pharmaceutical Co., Ltd . announced a phase II study plans to enroll a total of 208 patients with Acute Ischemic Stroke (AIS) who present within 4.5 to 24 hours of symptom onset and meet the specified imaging criteria.
* On June 24, 2026- Pharmazz, Inc . conducted a phase III clinical study to evaluate the safety and efficacy of sovateltide therapy along with standard of care in patients of acute ischemic stroke.
* On June 12, 2026- Supergene LLC highlighted a phase III clinical trial patients who had an acute ischaemic stroke due to anterior circulation large vessel occlusion (internal carotid artery, middle cerebral artery M1 and M2 segments) within 4.5-24 hours from last known well (including wake-up stroke and no witness stroke) and with salvageable tissue (ischaemic core volume
* On June 09, 2026- Boehringer Ingelheim conducted a phase 3 study is open to adults who had an acute stroke caused by a clot blocking a blood vessel in the brain (acute ischemic stroke). This study is for people who had an acute stroke or woke up with a stroke and were last seen well more than 4.5 hours before joining the study. Participants need to have imaging that shows there is brain tissue that can still be saved. They also should not be planned to receive a procedure to remove the blood clot.
* On June 02, 2026- Translational Sciences, Inc . initiated a study will randomize to 4 doses of TS23 and placebo. The trial will enroll up to 300 subjects at up to 60 participating US sites and up to 17 Canadian sites. SISTER is a Phase-II, prospective, randomized, placebo-controlled, blinded, dose finding trial that aims to determine the safety and preliminary efficacy of TS23, a monoclonal antibody against the alpha-2 antiplasmin (a2-AP), in acute ischemic stroke.
* DelveInsight's Ischemic Stroke pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for Ischemic Stroke treatment.
* The leading Ischemic Stroke Companies such as Genentech, Supergene, Tasly Pharmaceutical, Pharmazz, GNT Pharma, NoNO, Angde Biotech Pharmaceutical, ZZ Biotech, Bristol-Myers Squibb, Athersys, Bayer Healthcare, NuvOx Pharma, Healios, Acticor Biotech, DiaMedica Therapeutics, Moleac, Biogen, Revalesio Corporation, and Shijiazhuang Yiling Pharmaceutical Co and others.
* Promising Ischemic Stroke Pipeline Therapies such as Afamelanotide, Neflamapimod, Recombinant human urokinase, Alteplase, Aspirin, Ticagrelor, AX200 (G-CSF), Acetylsalicylic acid (ASA), Sovateltide, NXY-059 and others.

Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Ischemic Stroke Treatment Drugs [https://www.delveinsight.com/sample-request/ischemic-stroke-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Ischemic Stroke Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Ischemic Stroke Pipeline Report also highlights the unmet needs with respect to the development of Ischemic Stroke.

Ischemic Stroke Overview

Stroke is a leading cause of death and disability worldwide and can be broadly classified into ischaemic stroke and haemorrhagic stroke, the latter of which includes intracerebral haemorrhage and subarachnoid haemorrhage. Ischaemic stroke is defined as infarction of the brain, spinal cord or retina1 and represents ~71% of all strokes globally. Advances in brain imaging have shifted the definition of ischaemic stroke from a largely clinical determination to a tissue-based classification. Many transient events with full clinical recovery are now classed as stroke based on the identification of permanent tissue injury on MRI. A transient ischemic attack (TIA or mini-stroke) is the same as a stroke but the symptoms only last for a short amount of time. It is a major warning sign of a stroke and should always be taken seriously.

Ischemic Stroke Emerging Drugs Profile

* BMS-986177: Bristol-Myers Squibb/ Johnson & Johnson Innovative Medicine

Milvexian (BMS-986177) (Factor XIa) is an investigational anticoagulant compound. Factor XIa (FXIa) plays a key role in the activation and amplification of the coagulation cascade via the intrinsic pathway. A small study of Hemophilia C patients showed a lower risk of stroke. The drug is being developed by Bristol-Myers Squibb in collaboration with Johnson & Johnson. Currently the product is in Phase III stage of development for treatment of Ischemic Stroke.

* XY03 EA: Shijiazhuang Yiling Pharmaceutical Co. Ltd.

XY03 EA, is an investigational drug being developed by Shijiazhuang Yiling Pharmaceutical Co. Ltd. XY03-EA decreased the cerebral injuries and NDS by increasing cerebral blood flow, improving brain energy metabolism, accelerating ROS clearance, suppressing inflammatory responses, and inhibiting autophagy in the MCAO/R model rats. In the nonhuman primate MCAO/R model, the treatment of XY03-EA for 3 weeks could significantly inhibit the NDS progression rate and indicate a positive trend to reduce the infarct volume in a dose-dependent way. Mechanistically, XY03-EA inhibited ROS-dependent autophagy activation and thereby protected the PC-12 cells from the autophagic cell death induced by OGD/R. Currently the drug is in Phase II/III stage of Clinical trial evaluation for the treatment of Acute Ischemic Stroke.

* NONO-42: NoNO Inc.

NoNO-42 is a nerinetide analog intended for use in people experiencing an acute ischemic stroke with or without thrombolytics. Of the 650,000 people experiencing an acute ischemic stroke treated annually in US hospitals, approximately 10% receive a thrombolytic, which may reduce the applicability of nerinetide. Compatibility of NoNO-42 with thrombolytics broadens the availability neuroprotection and neurorestoration to all hospital treated strokes. Currently, the drug is in Phase II stage of its development for the treatment of acute ischemic stroke.

* hNPC01: Hopstem Biotechnology

hNPC01 refers to a novel cell therapy utilizing human induced pluripotent stem cell (iPSC)-derived human forebrain neural progenitor cells aimed at treating ischemic stroke. This therapy is particularly significant as it represents the first iPSC-derived product to receive FDA Investigational New Drug (IND) clearance for stroke treatment. Currently, the drug is in Phase I stage of its development for the treatment of acute ischemic stroke.

Explore groundbreaking therapies and clinical trials in the Ischemic Stroke Pipeline @ New Ischemic Stroke Drugs [https://www.delveinsight.com/sample-request/ischemic-stroke-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Ischemic Stroke Pipeline Report Provides Insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Ischemic Stroke with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ischemic Stroke Treatment.
* Ischemic Stroke Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Ischemic Stroke Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Ischemic Stroke market

Ischemic Stroke Companies

Genentech, Supergene, Tasly Pharmaceutical, Pharmazz, GNT Pharma, NoNO, Angde Biotech Pharmaceutical, ZZ Biotech, Bristol-Myers Squibb, Athersys, Bayer Healthcare, NuvOx Pharma, Healios, Acticor Biotech, DiaMedica Therapeutics, Moleac, Biogen, Revalesio Corporation, and Shijiazhuang Yiling Pharmaceutical Co and others.

Ischemic Stroke pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

Ischemic Stroke Products have been categorized under various Molecule types such as

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

Learn about new Ischemic Stroke Drugs and developments analysis @ Ischemic Stroke Market Drivers and Barriers [https://www.delveinsight.com/sample-request/ischemic-stroke-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Ischemic Stroke Pipeline Report

* Coverage- Global
* Ischemic Stroke Companies- Genentech, Supergene, Tasly Pharmaceutical, Pharmazz, GNT Pharma, NoNO, Angde Biotech Pharmaceutical, ZZ Biotech, Bristol-Myers Squibb, Athersys, Bayer Healthcare, NuvOx Pharma, Healios, Acticor Biotech, DiaMedica Therapeutics, Moleac, Biogen, Revalesio Corporation, and Shijiazhuang Yiling Pharmaceutical Co and others.
* Ischemic Stroke Pipeline Therapies- Afamelanotide, Neflamapimod, Recombinant human urokinase, Alteplase, Aspirin, Ticagrelor, AX200 (G-CSF), Acetylsalicylic acid (ASA), Sovateltide, NXY-059 and others.
* Ischemic Stroke Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Ischemic Stroke Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Download DelveInsight's in-depth Ischemic Stroke Pipeline Outlook Report today! @ Ischemic Stroke Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/ischemic-stroke-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Ischemic Stroke: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Ischemic Stroke- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* BMS-986177: Bristol-Myers Squibb/ Johnson & Johnson Innovative Medicine
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* XY03 EA: Shijiazhuang Yiling Pharmaceutical Co. Ltd.
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* hNPC01: Hopstem Biotechnology
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Ischemic Stroke Key Companies
* Ischemic Stroke Key Products
* Ischemic Stroke- Unmet Needs
* Ischemic Stroke- Market Drivers and Barriers
* Ischemic Stroke- Future Perspectives and Conclusion
* Ischemic Stroke Analyst Views
* Ischemic Stroke Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=ischemic-stroke-pipeline-gains-momentum-50-companies-lead-the-charge-in-pioneering-new-treatments-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/ischemic-stroke-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.